Developer docs
API playgroundTry for free, no card

Search company profiles

Gynecologic Cancer InterGroup

Full company profile

uuid003gjjc

Namestring
Gynecologic Cancer InterGroup
Legal namestring
Takläggare med ROT avdrag
Websiteurl
gciggroup.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

The Gynecologic Cancer InterGroup (GCIG) is described in its firmographic record as an organization that "aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer," implying a role as an international clinical-trial coordination consortium serving the gynecologic oncology research community. However, the scraped source material associated with the organization — the website at gciggroup.com — contains no content related to gynecologic cancer, clinical trials, oncology research, member institutions, or trial sponsors. Instead, the domain hosts a Swedish-language WordPress blog built on the ColorMag theme, publishing informational articles about home services including roofing (takläggare), kitchen renovation, moving services, floor sanding, moisture damage prevention, dental care, and address registration with Swedish authorities (Skatteverket). The site footer and legal metadata identify the operating entity as "Takläggare med ROT avdrag," and the geographic and regulatory references (Skatteverket, Personuppgiftslagen, ROT tax deduction) place the operational jurisdiction in Sweden. There is a clear identity-versus-content mismatch between the stated research mission and the actual web presence that any downstream user should weigh carefully.

No products, services, technology stack, pricing model, customer base, management team, funding rounds, or partnership network is disclosed for the organization in the source data. The website is a static content publication with no apparent monetization mechanism, no member portal, no trial registry integration, and no commercial offering. Operating status is active (copyright date 2026, recent article dates in 2023). No public listing, investor base, or corporate ownership structure is evidenced. As presented, the only observable business activity is the ongoing publication of Swedish home-services editorial content under a domain name that, by coincidence or repurposing, overlaps with the brand "Gynecologic Cancer InterGroup."

The mismatch between the stated clinical-trial coordination mission and the actual Swedish home-services blog footprint means the business model cannot be reliably characterized from the input. If the stated mission is accurate and the web presence is incidental or out of date, the organization would function as a non-commercial or membership-funded clinical-trial consortium; if the web presence reflects actual current activity, the entity operates as a Swedish affiliate-marketing or SEO content site unrelated to oncology. The source data does not resolve this ambiguity.

Short descriptiontext

According to its firmographic record, Gynecologic Cancer InterGroup aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer; however, the associated website (gciggroup.com) is a Swedish WordPress blog publishing home-services content, indicating an unresolved identity-versus-content mismatch.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
Markets served

Serves global market

Keyword5 values
gynecologic cancer research, clinical trial coordination, oncology research collaboration, cancer clinical trials, gynecologic oncology studies
Industry3 codes
1Gynecologic Oncology & Women’s Cancer Centers
CodeHLAFAJAKPrimaryYes
2Medical Oncology
CodeHLAKAFABPrimaryNo
3Gynecologic Oncology
CodeHLAKAJADPrimaryNo
NAICS code1 code
  • Offices of Physicians62111
SIC code1 code
  • Services-Health Services8000
Product category
Clinical Research
No data
Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gynecologic Cancer InterGroup aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer. The organization coordinates and supports collaborative oncology research across institutions involved in gynecologic cancer studies.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Gynecologic Cancer Clinical Trials Coordination
Description

Coordination of clinical trials aimed at improving outcomes for women with gynecologic cancer, facilitating collaborative research among participating institutions and investigators.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

One of the largest NCI-sponsored clinical trial cooperative groups in the U.S., formed from the merger of several oncology groups including the Gynecologic Oncology Group. Directly comparable as a multi-institutional gynecologic cancer trial coordinating organization.

TypeBroad incumbent
Description

Global professional society dedicated to gynecologic cancer research, education, and clinical trial promotion. Broader in scope than a trial cooperative but directly addresses the same patient population and research mission.

TypeBroad incumbent
Description

The U.S. federal agency leading the National Cancer Program and funding/coordinating a major share of oncology clinical trials. A structural incumbent and likely funding source or competitor for any gynecologic trial cooperative.

TypeDirect peer
Description

A pan-European network coordinating gynecological cancer clinical trials across national groups. Directly comparable in mission and intergroup structure to the subject company.

TypeBroad incumbent
Description

U.S.-based professional society for healthcare professionals specializing in gynecologic oncology. Comparable as a stakeholder and convener in the gynecologic cancer research community, though not a trial cooperative itself.

6Gynecologic Cancer InterGroup (GCIG)
TypeDirect peer
Description

An international collaboration of organizations performing gynecologic cancer clinical trials. Shares the subject company's name and exact stated mission, making it the most directly comparable entity; the data integrity issue with the subject's website domain heightens the relevance of this comparison.

7Primo Pharma Partners
TypeEmerging player
Description

An emerging clinical research organization focused on women's health and oncology trials. Comparable as a smaller, more specialized CRO-style operator in adjacent oncology/women's-health trial coordination.

TypeBroad incumbent
Description

One of the largest cancer research charities globally, running and funding clinical trials across multiple tumor types including gynecologic cancers. Comparable as a sponsor and coordinator of oncology clinical trials.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights2 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gynecologic Cancer InterGroup

Clinical Researchgciggroup.com

According to its firmographic record, Gynecologic Cancer InterGroup aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer; however, the associated website (gciggroup.com) is a Swedish WordPress blog publishing home-services content, indicating an unresolved identity-versus-content mismatch.

What Gynecologic Cancer InterGroup does

The Gynecologic Cancer InterGroup (GCIG) is described in its firmographic record as an organization that "aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer," implying a role as an international clinical-trial coordination consortium serving the gynecologic oncology research community. However, the scraped source material associated with the organization — the website at gciggroup.com — contains no content related to gynecologic cancer, clinical trials, oncology research, member institutions, or trial sponsors. Instead, the domain hosts a Swedish-language WordPress blog built on the ColorMag theme, publishing informational articles about home services including roofing (takläggare), kitchen renovation, moving services, floor sanding, moisture damage prevention, dental care, and address registration with Swedish authorities (Skatteverket). The site footer and legal metadata identify the operating entity as "Takläggare med ROT avdrag," and the geographic and regulatory references (Skatteverket, Personuppgiftslagen, ROT tax deduction) place the operational jurisdiction in Sweden. There is a clear identity-versus-content mismatch between the stated research mission and the actual web presence that any downstream user should weigh carefully.

No products, services, technology stack, pricing model, customer base, management team, funding rounds, or partnership network is disclosed for the organization in the source data. The website is a static content publication with no apparent monetization mechanism, no member portal, no trial registry integration, and no commercial offering. Operating status is active (copyright date 2026, recent article dates in 2023). No public listing, investor base, or corporate ownership structure is evidenced. As presented, the only observable business activity is the ongoing publication of Swedish home-services editorial content under a domain name that, by coincidence or repurposing, overlaps with the brand "Gynecologic Cancer InterGroup."

The mismatch between the stated clinical-trial coordination mission and the actual Swedish home-services blog footprint means the business model cannot be reliably characterized from the input. If the stated mission is accurate and the web presence is incidental or out of date, the organization would function as a non-commercial or membership-funded clinical-trial consortium; if the web presence reflects actual current activity, the entity operates as a Swedish affiliate-marketing or SEO content site unrelated to oncology. The source data does not resolve this ambiguity.

Gynecologic Cancer InterGroup firmographics

Firmographics
Name
Gynecologic Cancer InterGroup
Legal name
Takläggare med ROT avdrag
Website
https://gciggroup.com
Company type
Private
Operating status
Operating
Short description
According to its firmographic record, Gynecologic Cancer InterGroup aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer; however, the associated website (gciggroup.com) is a Swedish WordPress blog publishing home-services content, indicating an unresolved identity-versus-content mismatch.
Ownership category
akta.pro rank

Gynecologic Cancer InterGroup industry classification

Industry
Product category
Clinical Research
NAICS
Offices of Physicians (62111)
SIC
Services-Health Services (8000)
akta.pro primary industry
Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)
akta.pro secondary industries
Medical Oncology (HLAKAFAB), Gynecologic Oncology (HLAKAJAD)

Keywords

  • Gynecologic cancer research
  • Clinical trial coordination
  • Oncology research collaboration
  • Cancer clinical trials
  • Gynecologic oncology studies

Gynecologic Cancer InterGroup business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Gynecologic Cancer InterGroup product offering

Product offering

Core offering

Gynecologic Cancer InterGroup aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer. The organization coordinates and supports collaborative oncology research across institutions involved in gynecologic cancer studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gynecologic Cancer Clinical Trials Coordination Coordination of clinical trials aimed at improving outcomes for women with gynecologic cancer, facilitating collaborative research among participating institutions and investigators.

Companies that use Gynecologic Cancer InterGroup

Customer profile

Ideal customer profiles1 record

Gynecologic Cancer InterGroup technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gynecologic Cancer InterGroup partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Gynecologic Cancer InterGroup competitors and assessment

Company assessment

Direct peers

  • NRG Oncology: One of the largest NCI-sponsored clinical trial cooperative groups in the U.S., formed from the merger of several oncology groups including the Gynecologic Oncology Group. Directly comparable as a multi-institutional gynecologic cancer trial coordinating organization.
  • European Network of Gynaecological Oncological Trial Groups (ENGOT): A pan-European network coordinating gynecological cancer clinical trials across national groups. Directly comparable in mission and intergroup structure to the subject company.
  • Gynecologic Cancer InterGroup (GCIG): An international collaboration of organizations performing gynecologic cancer clinical trials. Shares the subject company's name and exact stated mission, making it the most directly comparable entity; the data integrity issue with the subject's website domain heightens the relevance of this comparison.

Broad incumbents

  • International Gynecologic Cancer Society (IGCS): Global professional society dedicated to gynecologic cancer research, education, and clinical trial promotion. Broader in scope than a trial cooperative but directly addresses the same patient population and research mission.
  • National Cancer Institute (NCI): The U.S. federal agency leading the National Cancer Program and funding/coordinating a major share of oncology clinical trials. A structural incumbent and likely funding source or competitor for any gynecologic trial cooperative.
  • Society of Gynecologic Oncology (SGO): U.S.-based professional society for healthcare professionals specializing in gynecologic oncology. Comparable as a stakeholder and convener in the gynecologic cancer research community, though not a trial cooperative itself.
  • Cancer Research UK Clinical Trials Unit: One of the largest cancer research charities globally, running and funding clinical trials across multiple tumor types including gynecologic cancers. Comparable as a sponsor and coordinator of oncology clinical trials.

Emerging players

  • Primo Pharma Partners: An emerging clinical research organization focused on women's health and oncology trials. Comparable as a smaller, more specialized CRO-style operator in adjacent oncology/women's-health trial coordination.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks4 records

Key highlights2 records

Customer concentration

Gynecologic Cancer InterGroup financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gynecologic Cancer InterGroup leadership team

Management profile

Number of profiles

Gynecologic Cancer InterGroup funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gynecologic Cancer InterGroup M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gynecologic Cancer InterGroup

What does Gynecologic Cancer InterGroup do?

Gynecologic Cancer InterGroup aims to promote and facilitate quality clinical trials to improve outcomes for women with gynecologic cancer. The organization coordinates and supports collaborative oncology research across institutions involved in gynecologic cancer studies.

Is Gynecologic Cancer InterGroup a public or private company?

Gynecologic Cancer InterGroup is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Gynecologic Cancer InterGroup founded?

Gynecologic Cancer InterGroup was founded in -1.

Who are Gynecologic Cancer InterGroup's main competitors?

Direct peers on record are NRG Oncology, European Network of Gynaecological Oncological Trial Groups (ENGOT) and Gynecologic Cancer InterGroup (GCIG). Broad incumbents are International Gynecologic Cancer Society (IGCS), National Cancer Institute (NCI), Society of Gynecologic Oncology (SGO) and Cancer Research UK Clinical Trials Unit. Primo Pharma Partners is listed as an emerging player.

Does Gynecologic Cancer InterGroup have an API?

No public API is recorded for Gynecologic Cancer InterGroup.

What industry is Gynecologic Cancer InterGroup in?

Gynecologic Cancer InterGroup's product category is Clinical Research. Its primary akta.pro industry code is HLAFAJAK, Gynecologic Oncology & Women’s Cancer Centers, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 62111 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales